M. Lucena

Drug-induced liver injury

P. Watkins, N. Chalasani, R. Andrade, 2019, Nature Reviews Disease Primers.

Causality assessment in drug-induced hepatotoxicity

R. Andrade, M. Lucena, R. González‐Grande, 2004, Expert opinion on drug safety.

Causality assessment methods in drug induced liver injury: strengths and weaknesses.

C. Stephens, R. Andrade, M. Lucena, 2011, Journal of hepatology.

AUTOIMMUNE, CHOLESTATIC AND BILIARY DISEASE The Use of Liver Biopsy Evaluation in Discrimination of Idiopathic Autoimmune Hepatitis Versus Drug-Induced Liver Injury

A. Suzuki, E. Björnsson, K. Lindor, 2011 .

Trends in Qualifying Biomarkers in Drug Safety. Consensus of the 2011 Meeting of the Spanish Society of Clinical Pharmacology

C. Stephens, R. Andrade, M. Lucena, 2012, Front. Pharmacol..

Tandem mass tag­based quantitative proteomic profiling identifies novel serum biomarkers of drug­induced liver injury in humans

R. Everley, C. Stephens, R. Andrade, 2023 .

Neddylation inhibition prevents acetaminophen-induced liver damage by enhancing the anabolic cardiolipin pathway

U. Mayor, L. A. Martínez-Cruz, R. Nogueiras, 2024, Cell reports. Medicine.

Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug‐induced idiosyncratic liver injury (DILI)

F. Ruiz-Cabello, K. Pachkoria, M. Cabello, 2007, British journal of pharmacology.